Research programme: obesity therapy - Nanodesign

Drug Profile

Research programme: obesity therapy - Nanodesign

Alternative Names: Obesity therapy research programme - Nanodesign

Latest Information Update: 20 Nov 2002

Price : $50

At a glance

  • Originator Nanodesign (CEASED); SignalGene [CEASED]
  • Class
  • Mechanism of Action ERRalpha estrogen-related receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 20 Nov 2002 Discontinued - Preclinical for Obesity in Canada (unspecified route)
  • 21 May 2001 This programme is available for licensing or co-development (http://www.nanodesign.com)
  • 16 Jan 2001 Preclinical development for Obesity in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top